Draft:Bamlanivimab

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries

Retrieved on: 
Tuesday, May 4, 2021
Medical specialties, Medicine, Clinical medicine, Antiviral drugs, COVID-19 drug development, Monoclonal antibodies, Bamlanivimab, AbCellera, Treatment and management of COVID-19, COVID-19, Direct Relief, Draft:Bamlanivimab

This donation furthers both Lilly and Direct Relief\'s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries.

Key Points: 
  • This donation furthers both Lilly and Direct Relief\'s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries.
  • This is a wonderful example of each of us doing whatever we can to get through this pandemic," said Direct Relief president and CEO Thomas Tighe.
  • "\nThe allocation of therapies will be based on the disease burden and hospitalization rates in each country.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

Retrieved on: 
Wednesday, March 10, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Drugs, Health sciences, Health, COVID-19 drug development, Monoclonal antibodies, Antiviral drugs, Bamlanivimab, Coronavirus disease, Clinical trial, Draft:Bamlanivimab

No COVID-19-related deaths have been observed across the thousands of patients who have been treated with bamlanivimab alone or together with etesevimab in clinical trials.

Key Points: 
  • No COVID-19-related deaths have been observed across the thousands of patients who have been treated with bamlanivimab alone or together with etesevimab in clinical trials.
  • These antibody therapies can be powerful tools in keeping COVID-19 patients out of the hospital and preventing death.
  • A safety profile consistent with those observed from other Phase 1, Phase 2, and Phase 3 trials evaluating these antibodies.
  • Bamlanivimab alone and together with etesevimab are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union.

U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy

Retrieved on: 
Friday, February 26, 2021
Drugs, COVID-19 drug development, Medical specialties, Antiviral drugs, Monoclonal antibodies, Medicine, Bamlanivimab, Draft:Bamlanivimab, AbCellera, Peplomer, Coronavirus disease, Neutralizing antibody

The government has said it will provide neutralizing antibodies at no out-of-pocket cost to patients, although healthcare facilities may charge a fee for the product's administration.

Key Points: 
  • The government has said it will provide neutralizing antibodies at no out-of-pocket cost to patients, although healthcare facilities may charge a fee for the product's administration.
  • The federal government directs the distribution of etesevimab and bamlanivimab together.
  • Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19

Retrieved on: 
Wednesday, January 27, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious diseases, Other Health, Medical specialties, Clinical medicine, Medicine, COVID-19 drug development, Antiviral drugs, Monoclonal antibodies, Immunology, Bamlanivimab, AbCellera, Draft:Bamlanivimab, Biotechnology, Coronavirus disease, AbCellera’s Response to COVID-19, Bamlanivimab, AbCellera Biologics Inc.

Bamlanivimab is currently a component in all Lillys antibody-based COVID-19 therapies, which include bamlanivimab alone, and bamlanivimab and etesevimab together.

Key Points: 
  • Bamlanivimab is currently a component in all Lillys antibody-based COVID-19 therapies, which include bamlanivimab alone, and bamlanivimab and etesevimab together.
  • The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.
  • Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at NIAID VRC.

AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents

Retrieved on: 
Thursday, January 21, 2021
Research, Nursing, Infectious diseases, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Medical specialties, Clinical medicine, Medicine, Immunology, Antiviral drugs, Monoclonal antibodies, Bamlanivimab, COVID-19 drug development, AbCellera, Antibodies, Neutralizing antibody, Draft:Bamlanivimab, AbCellera’s Response to COVID-19, Bamlanivimab, AbCellera Biologics Inc.

Furthermore, data obtained from the treatment group are completely consistent with what was observed in the BLAZE-1 trial.

Key Points: 
  • Furthermore, data obtained from the treatment group are completely consistent with what was observed in the BLAZE-1 trial.
  • This reinforces the importance of efforts to ensure high-risk patients get access to antibody therapy early in COVID-19 infection.
  • The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico

Retrieved on: 
Monday, December 21, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Medical specialties, Medicine, Draft:Bamlanivimab, Clinical medicine, Immune system, Antibodies, AbCellera, Coronavirus disease, Monoclonal antibody, Neutralizing antibody, Bamlanivimab, AbCellera Biologics Inc.

As part of this study, Lilly will employ its unique mobile research units used successfully in other studies.

Key Points: 
  • As part of this study, Lilly will employ its unique mobile research units used successfully in other studies.
  • By deploying on-site infusion clinics, Lilly continues to lead in finding ways to bring antibody treatments to patients, said Carl Hansen, Ph.D., CEO of AbCellera.
  • Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.

Principle LTC's Tower Nursing & Rehabilitation Center Joins with Eli Lilly and Company on Phase 3 Drug Trial for COVID-19 Prevention

Retrieved on: 
Monday, December 21, 2020
Health, Occupational safety and health, Articles, Eli Lilly and Company, LLY, Coronavirus disease, COVID-19 pandemic, Eli Lilly, Draft:Bamlanivimab

RALEIGH, N.C., Dec.21, 2020 /PRNewswire/ -- Principle LTC's Tower Nursing & Rehabilitation Center announced today it has partnered with Eli Lilly and Company of Indianapolis (NYSE: LLY) in a Phase 3 clinical trial evaluating bamlanivimab (LY-CoV555), alone or in combination with etesevimab (LY-CoV016).

Key Points: 
  • RALEIGH, N.C., Dec.21, 2020 /PRNewswire/ -- Principle LTC's Tower Nursing & Rehabilitation Center announced today it has partnered with Eli Lilly and Company of Indianapolis (NYSE: LLY) in a Phase 3 clinical trial evaluating bamlanivimab (LY-CoV555), alone or in combination with etesevimab (LY-CoV016).
  • Early data has demonstrated that bamlanivimab can keep patients in the early stages of COVID-19 from developing more severe symptoms that require hospitalization.
  • Principle LTC and Tower's continued response to the COVID-19 pandemic is focused on the safety of staff, residents, and the surrounding community.
  • Our entire organization at Principle has been battling to find the newest and best methods to assist in the prevention and treatment.

DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies

Retrieved on: 
Friday, November 27, 2020
Medical specialties, Medicine, Clinical medicine, Immunology, Immune system, Antibodies, Neutralizing antibody, Coronavirus disease, Monoclonal antibody, Draft:Bamlanivimab

STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.

Key Points: 
  • STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.
  • For this Gene MAb approach, the SmartPharm/Sorrento team will produce plasmid DNA encoding the SARS-CoV-2 neutralizing antibody STI-2020 (COVI-AMG).
  • The FDA is currently reviewing IND filings for STI-2020 as an IV-delivered neutralizing antibody and STI-2099 as an intranasal-delivered neutralizing antibody for the treatment of COVID-19.
  • The expected higher potency of the STI-2020 antibody makes it an ideal candidate for Gene MAb delivery against COVID-19.

AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19

Retrieved on: 
Friday, November 20, 2020
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Life sciences, Health sciences, Biotechnology, Pharmaceutical industry, Draft:Bamlanivimab, AbCellera, Emergency Use Authorization, Eua, Food and Drug Administration, Biopharmaceutical, Bamlanivimab, BLAZE-1, AbCellera Biologics Inc.

Details regarding the interim authorization can be found here .

Key Points: 
  • Details regarding the interim authorization can be found here .
  • Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020.
  • Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.
  • AbCellera's partners include leading biotechnology companies, global health organizations, and many of the top 10 biopharmaceutical companies.

Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19

Retrieved on: 
Monday, November 16, 2020
Medical specialties, Medicine, Clinical medicine, Immunology, Antibodies, Immune system, Glycoproteins, Neutralizing antibody, Coronavirus disease, Monoclonal antibody, Draft:Bamlanivimab, COVID-19 drug development

Data support the continued evaluation of neutralizing antibody therapeutic, ABP 300, in human subjects

Key Points: 
  • Data support the continued evaluation of neutralizing antibody therapeutic, ABP 300, in human subjects
    WOBURN, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Abpro Corporation today announced the publication of a peer-reviewed article in the scientific journal Nature Communications titled, Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
  • We are highly encouraged by this preclinical best-in-class proof-of-concept data showing the potential of our monoclonal antibodies to neutralize multiple SARS-CoV-2 strains.
  • The data supports further development of antibody-based therapies for prophylactic and therapeutic treatment of COVID-19, said Ian Chan,chief executive officer and co-founderofAbproCorporation.
  • ABP 300 is a human neutralizing monoclonal antibody therapy against COVID-19 that was created using the latest technologies available for antibody discovery.